India’s snakebite treatment relies on a single, fragile link in its supply chain: the Irular Co-Operative Society in Tamil Nadu, the country’s only licensed venom supplier. For decades, antivenom manufacturers have depended on Irular’s snake catchers to milk the “Big Four” snakes—cobras, kraits, Russell’s vipers, and saw-scaled vipers. But according to Dr. Darshan Patel, General Manager, Plant Head (Operations, Quality & Projects), ViNSBioproducts,Irular’s venom is “low-quality”, forcing producers to apply extra filtration that discards valuable toxins and directly erodes antivenom potency across India.
The problem begins with inconsistent venom composition. Irular Co-Op pools venom from snakes captured across Tamil Nadu, but research from IISc shows that venom from the same species varies dramatically between districts. A cobra from Chennai’s wetlands differs genetically and toxicologically from a cobra in the dry Tirunelveli plains. When Irular ships pooled venom to manufacturers like ViNS and Biological E., the immunogen is a molecular lottery—some batches are rich in neurotoxins, others in hemotoxins, none perfectly matched to the snakes that bite patients in Rajasthan or West Bengal.
Dr. Patel, during his interviews with various media organisations, explains the downstream consequence: “We have to filter it more, which means we lose venom.” Every filtration step removes proteins, including the very toxins needed to hyperimmunize horses. The result is weaker plasma, which yields antivenom with lower neutralizing potency. A 2025 field investigation found that ViNS’s antivenom, produced from Irular venom, showed poor binding to venom from North Indian cobras, with neutralization capacity dropping by up to 40% against some regional populations. This is not a manufacturing defect—it is a raw material crisis.
The crisis is amplified by fragmented production. Bharat Serums, unwilling to shoulder the cost and risk of horse farming, sold its farm and now outsources plasma entirely to Raut Serums, which also supplies ViNS and others. Horses cannot be switched between venom schemes; a horse immunized with Indian venom cannot be repurposed for African antivenom. When disease outbreaks sweep through Raut’s 150-acre facility—“flu season” can stall production for weeks—the entire national supply chain seizes.
The human cost is stark. India records 58,000 snakebite deaths annually, and many victims receive antivenom that was never designed for their local snake. The Irular Co-Op’s monopoly means there is no alternative venom source to validate or compare quality. Until India establishes regional venom banks and supports synthetic recombinant platforms that bypass both snakes and horses, the “low-quality venom” problem will continue to undermine every vial of antivenom—no matter how pure the final product looks in the lab.
– Macha Madhu
